Advertisement

Solid Lipid Nanoparticles: A Modern Approach for the Treatment of Neurodegenerative Diseases

  • Anisha A. D’Souza
Chapter

Abstract

Targeting drugs to the Central nervous system (CNS) for any CNS related disorders has been a herculean task mainly due to the inability of drugs to cross the blood-brain barrier and blood-cerebrospinal fluid barrier. Nanotechnology has been widely adopted to overcome this shortcoming. Solid lipid nanoparticles have been suggested as successful among the different Nano Drug Delivery systems. The increased chances of traversing the blood brain barrier by the lipid components of solid lipid nanoparticles is notable in addition to the other benefits offered by nanoparticles. The current chapter discusses the application of solid lipid nanoparticles in neurodegenerative diseases.

References

  1. Aggarwal P, Hall JB, Mcleland CB et al (2009) Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61:428–437CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bhaskar S, Tian F, Stoeger T et al (2010) Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 7:3CrossRefPubMedPubMedCentralGoogle Scholar
  3. Bhatt R, Singh D, Prakash A et al (2015) Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington’s disease. Drug Deliv 22:931–939CrossRefPubMedGoogle Scholar
  4. Bodor N, Buchwald P (1999) Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev 36:229–254CrossRefPubMedGoogle Scholar
  5. Bondi ML, Craparo EF, Giammona G et al (2010) Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. Nanomedicine (Lond) 5:25–32CrossRefGoogle Scholar
  6. Burla C, Rego G, Nunes R (2014) Alzheimer, dementia and the living will: a proposal. Med Health Care Philos 17:389–395CrossRefPubMedPubMedCentralGoogle Scholar
  7. Cacciatore I, Ciulla M, Fornasari E et al (2016) Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opin Drug Deliv 13:1121–1131CrossRefPubMedGoogle Scholar
  8. Cecchelli R, Berezowski V, Lundquist S et al (2007) Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 6:650–661CrossRefPubMedGoogle Scholar
  9. Chen Y, Liu L (2012) Modern methods for delivery of drugs across the blood–brain barrier. Adv Drug Deliv Rev 64:640–665CrossRefPubMedGoogle Scholar
  10. Clark DE (2003) In silico prediction of blood-brain barrier permeation. Drug Discov Today 8:927–933CrossRefPubMedGoogle Scholar
  11. D’Souza AA, Devarajan PV (2015) Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications. J Control Release 203:126–139CrossRefPubMedGoogle Scholar
  12. D’Souza AA, Shegokar R (2016) Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv 13:1257–1275CrossRefPubMedGoogle Scholar
  13. Dang H, Meng MHW, Zhao H et al (2014) Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies. J Nanopart Res 16:2347CrossRefGoogle Scholar
  14. De Lau LML, Breteler MMB (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535CrossRefPubMedGoogle Scholar
  15. Derossi D, Calvet S, Trembleau A et al (1996) Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 271:18188–18193CrossRefPubMedGoogle Scholar
  16. Dhawan S, Kapil R, Singh B (2011) Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol 63:342–351CrossRefPubMedGoogle Scholar
  17. Dwibhashyam V, Nagappa AN (2008) Strategies for enhanced drug delivery to the central nervous system. Indian J Pharm Sci 70:145–153CrossRefPubMedPubMedCentralGoogle Scholar
  18. Esposito E, Fantin M, Marti M et al (2008) Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res 25:1521–1530CrossRefPubMedGoogle Scholar
  19. Farokhzad OC, Langer R (2006) Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 58:1456–1459CrossRefPubMedGoogle Scholar
  20. Gobbi M, Re F, Canovi M et al (2010) Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 31:6519–6529CrossRefPubMedGoogle Scholar
  21. Goldsmith M, Abramovitz L, Peer D (2014) Precision nanomedicine in neurodegenerative diseases. ACS Nano 8:1958–1965CrossRefPubMedGoogle Scholar
  22. Goyal K, Koul V, Singh Y et al (2014) Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances. Cent Nerv Syst Agents Med Chem 14:43–59CrossRefPubMedGoogle Scholar
  23. Gupta Y, Jain A, Jain SK (2007) Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 59:935–940CrossRefPubMedGoogle Scholar
  24. Huwyler J, Wu D, Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci 93:14164–14169CrossRefPubMedGoogle Scholar
  25. Jankovic J, Stacy M (2007) Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs 21:677–692CrossRefPubMedGoogle Scholar
  26. Ji H, Tang J, Li M et al (2016) Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin. Drug Deliv 23:459–470CrossRefPubMedGoogle Scholar
  27. Jogani V, Jinturkar K, Vyas T et al (2008) Recent patents review on intranasal administration for CNS drug delivery. Recent Pat Drug Deliv Formul 2:25–40CrossRefPubMedGoogle Scholar
  28. Kakkar V, Kaur IP (2011) Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem Toxicol 49:2906–2913CrossRefPubMedGoogle Scholar
  29. Kang YS, Bickel U, Pardridge WM (1994) Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Drug Metab Dispos 22:99–105PubMedGoogle Scholar
  30. Kanwar JR, Sriramoju B, Kanwar RK (2012) Neurological disorders and therapeutics targeted to surmount the blood-brain barrier. Int J Nanomedicine 7:3259–3278CrossRefPubMedPubMedCentralGoogle Scholar
  31. Kaur IP, Bhandari R, Bhandari S et al (2008) Potential of solid lipid nanoparticles in brain targeting. J Control Release 127:97–109CrossRefPubMedGoogle Scholar
  32. Kravcik S, Gallicano K, Roth V et al (1999) Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acquir Immune Defic Syndr 21:371–375CrossRefPubMedGoogle Scholar
  33. Kulkarni SA, Feng SS (2011) Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier. Nanomedicine (Lond) 6:377–394CrossRefGoogle Scholar
  34. Kumar A, Singh TD, Singh SK et al (2009) Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells. Biologics 3:245–256PubMedPubMedCentralGoogle Scholar
  35. Laserra S, Basit A, Sozio P et al (2015) Solid lipid nanoparticles loaded with lipoyl-memantine codrug: preparation and characterization. Int J Pharm 485:183–191CrossRefPubMedGoogle Scholar
  36. Li J, Li T, Zhang X et al (2014) Human superoxide dismutase 1 overexpression in motor neurons of Caenorhabditis elegans causes axon guidance defect and neurodegeneration. Neurobiol Aging 35:837–846CrossRefPubMedGoogle Scholar
  37. Lin CH, Chen CH, Lin ZC et al (2017) Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J Food Drug Anal 25:219–234CrossRefPubMedGoogle Scholar
  38. Madrid Y, Langer LF, Brem H et al (1991) New directions in the delivery of drugs and other substances to the central nervous system. In: August JT, Anders MW, Murad F (eds) Advances in pharmacology. Academic Press, New YorkGoogle Scholar
  39. Mendez-Huergo SP, Maller SM, Farez MF et al (2014) Integration of lectin-glycan recognition systems and immune cell networks in CNS inflammation. Cytokine Growth Factor Rev 25:247–255CrossRefPubMedGoogle Scholar
  40. Misra S, Chopra K, Sinha VR et al (2016) Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv 23:1434–1443CrossRefPubMedGoogle Scholar
  41. Moghimi SM, Porter CJ, Muir IS et al (1991) Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun 177:861–866CrossRefPubMedGoogle Scholar
  42. Montenegro L, Campisi A, Sarpietro MG et al (2011) In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm 37:737–746CrossRefPubMedGoogle Scholar
  43. Müller RH, Radtke M, Wissing SA (2002) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54:S131–S155CrossRefPubMedGoogle Scholar
  44. Orlando A, Re F, Sesana S et al (2013) Effect of nanoparticles binding β-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages. Int J Nanomedicine 8:1335–1347CrossRefPubMedPubMedCentralGoogle Scholar
  45. Pandita D, Kumar S, Poonia N et al (2014) Solid lipid nanoparticles enhance oral bioavailability of resveratrol, a natural polyphenol. Food Res Int 62:1165–1174CrossRefGoogle Scholar
  46. Pardeshi CV, Rajput PV, Belgamwar VS et al (2013) Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach. Drug Deliv 20:47–56CrossRefPubMedGoogle Scholar
  47. Pardridge WM (1988) Recent advances in blood-brain barrier transport. Annu Rev Pharmacol Toxicol 28:25–39CrossRefPubMedGoogle Scholar
  48. Pardridge WM (2010) Biopharmaceutical drug targeting to the brain. J Drug Target 18:157–167CrossRefPubMedGoogle Scholar
  49. Pathan SA, Iqbal Z, Zaidi SM et al (2009) CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul 3:71–89CrossRefPubMedGoogle Scholar
  50. Picone P, Bondi ML, Montana G et al (2009) Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: improved delivery by solid lipid nanoparticles. Free Radic Res 43:1133–1145CrossRefPubMedGoogle Scholar
  51. Rajput AH (1992) Frequency and cause of Parkinson’s disease. Can J Neurol Sci 19:103–107PubMedGoogle Scholar
  52. Ramalingam P, Ko YT (2016) Improved oral delivery of resveratrol from N-trimethyl chitosan-g-palmitic acid surface-modified solid lipid nanoparticles. Colloids Surf B Biointerfaces 139:52–61CrossRefPubMedGoogle Scholar
  53. Sakane T, Akizuki M, Yamashita S et al (1994) Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the dissociation of the drug. J Pharm Pharmacol 46:378–379CrossRefPubMedGoogle Scholar
  54. Samii A, Nutt JG, Ransom BR (2004) Parkinson’s disease. Lancet 363:1783–1793CrossRefPubMedGoogle Scholar
  55. Sandhir R, Yadav A, Mehrotra A et al (2014) Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington’s disease. NeuroMolecular Med 16:106–118CrossRefPubMedGoogle Scholar
  56. Saykin AJ, Wishart HA, Rabin LA et al (2004) Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 127:1574–1583CrossRefPubMedGoogle Scholar
  57. Smith A, Giunta B, Bickford PC et al (2010) Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer’s disease. Int J Pharm 389:207–212CrossRefPubMedPubMedCentralGoogle Scholar
  58. Souto EB, Muller RH, Gohla S (2005) A novel approach based on lipid nanoparticles (SLN) for topical delivery of alpha-lipoic acid. J Microencapsul 22:581–592CrossRefPubMedGoogle Scholar
  59. Spuch C, Saida O, Navarro C (2012) Advances in the treatment of neurodegenerative disorders employing nanoparticles. Recent Pat Drug Deliv Formul 6:2–18CrossRefPubMedGoogle Scholar
  60. Thorne RG, Frey WH 2nd (2001) Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 40:907–946CrossRefPubMedGoogle Scholar
  61. Townsend SA, Evrony GD, Gu FX et al (2007) Tetanus toxin C fragment-conjugated nanoparticles for targeted drug delivery to neurons. Biomaterials 28:5176–5184CrossRefPubMedPubMedCentralGoogle Scholar
  62. Tsai MJ, Huang YB, Wu PC et al (2011) Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci 100:547–557CrossRefPubMedGoogle Scholar
  63. Vedagiri A, Thangarajan S (2016) Mitigating effect of chrysin loaded solid lipid nanoparticles against Amyloid beta25-35 induced oxidative stress in rat hippocampal region: an efficient formulation approach for Alzheimer’s disease. Neuropeptides 58:111–125CrossRefPubMedGoogle Scholar
  64. Vives E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272:16010–16017CrossRefPubMedGoogle Scholar
  65. Vytla D, Combs-Bachmann RE, Hussey AM et al (2012) Prodrug approaches to reduce hyperexcitation in the CNS. Adv Drug Deliv Rev 64:666–685CrossRefPubMedGoogle Scholar
  66. Wang PP, Frazier J, Brem H (2002) Local drug delivery to the brain. Adv Drug Deliv Rev 54:987–1013CrossRefPubMedGoogle Scholar
  67. Wu J, Yoon S-H, Wu W-M et al (2002) Synthesis and biological evaluations of brain-targeted chemical delivery systems of [Nva2]-TRH. J Pharm Pharmacol 54:945–950CrossRefPubMedGoogle Scholar
  68. Yoo JY, Kim JM, Seo KS et al (2005) Characterization of degradation behavior for PLGA in various pH condition by simple liquid chromatography method. Biomed Mater Eng 15:279–288PubMedGoogle Scholar
  69. Yusuf M, Khan M, Khan RA et al (2013) Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model. J Drug Target 21:300–311CrossRefGoogle Scholar
  70. Zhan S, Hou D, Ping Q et al (2010) Preparation and entrapment efficiency determination of solid lipid nanoparticles loaded levodopa. Zhongguo Yiyuan Yaoxue Zazhi 30:1171–1175Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Anisha A. D’Souza
    • 1
  1. 1.Formulation Development LaboratoryPharmaceutical R&D, Piramal Enterprises LimitedMumbaiIndia

Personalised recommendations